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S214 Poster Session Iensuing 3 mo. By contrast, CAR.19z cells were barely detectable af-
ter infusion, showed no expansion and disappeared rapidly. Follow-
ing treatment, 2 patients had stable disease for up to 6 mo and 4 had
progressive disease.
In conclusion, infusion of both CAR.19z and CD19-28zT cells is
safe at the doses used. Direct comparison of each cell product in
individual patients showed that the CD28 endodomain enhances
expansion and persistence of the CAR T cells. The limited clinical
benefits suggest that additional modifications will be required and
our approach will allow these changes to be systematically evaluated
even in small-scale clinical studies.164
BK VIRUS SPECIFIC T CELLS EXPANDED EX VIVO FOR USE IN CELLULAR
THERAPY SHOW MULTIPLE ANTIGEN SPECIFICITY AND POLYFUNC-
TIONAL TH1 RESPONSES
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There is increasing evidence for the role of BK virus in the aetiol-
ogy of haemorrhagic cystitis and renal impairment post haemo-
poietic stem cell transplant (HSCT). Cellular therapy for immune
reconstitution post HSCT has been used clinically for CMV, EBV
and adenovirus. Broadening the scope of viral targets in this type
of therapy is desirable to reduce the burden of opportunistic infec-
tions in this patient group.
Methods: Monocyte derived dendritic cells or peripheral blood
mononuclear cells were pulsed with mixes of overlapping peptides
covering the 5 BKV proteins (VP1, VP2, VP3, LTA and STA).
These were used to stimulate T cells on days 1 and 7 and cells
were cultured for 21 days with increasing doses of IL-2 from day
7. The cellular product was then analysed for phenotype, BKV spec-
ificity and functionality by examining cytokine production and
cytotoxicity.
Results: Cellular proliferation was seen in all donors, mean fold in-
crease in total viable cells was 5.9 fold. All cell products were mainly
CD3 cells (mean 94.1%) with individual variation in CD4:CD8 ratio
(ranges: CD4 9.7 to 97.5%; CD8 0.9 to 77%). T cell subsets analysis
showed the majority of cells to be Tem (mean 71.2%), with a sizable
minority of Tcm (mean 21.5%). Data on antigen specificity was
available in 11 of 15 cultures. Within cultures, BKV responsive cells
varied (CD3 mean 12.7%, CD8 mean 15.2%, CD4 mean 12.5%,).
There was heterogeneity in the specificity of cells to different BKV
proteins. Most responses were directed to VP1, LTA and STA
with smaller magnitude responses seen to VP2 and VP3. The quality
of the cytokine response was assessed bymultiparameter flow cytom-
etry for IFN-g, TNF and IL-2. In all cases, the percentage of cells
producing multiple cytokines to stimulation with BKV proteins
was high (for CD3 mean triple cytokine 37.5%, double 34.3% and
single 28.2%). Cytotoxicity was assessed using CD107a/b expression
and the CARE-LASS cell lysis assay. CD107 expression was present
in both CD8 and CD4. This was higher in CD8 cells and lysis of
antigen coated target cells correlatedwith the presence of CD107 ex-
pression on CD8 cells.
Discussion:The clinical utility of this product will be determined in
clinical trials of adoptive immunotherapy following HSCT or renal
transplantation. This method for large-scale expansion of BKV spe-
cific CTL could also be utilised for analysis of BKV targeted immune
responses and epitope identification.165
EXPANDED HUMAN INKT CELLS EXHIBIT TH2 POLARIZATION AND
DIRECT CYTOTOXICITY AGAINST HEMATOLYMPHOID TUMOR TARGETS
Luszczek, W.1, Morales-Tirado, V.1, Woolard, S.N.1, Van Der
Merwe,M.1, Shook, D.1,2, Campana, D.2, Pillai, A.1 1St. Jude Children’s
Research Hospital, Memphis, TN; 2St. Jude Children’s Research Hospital,
Memphis, TNCD1d-restricted invariant NKT (iNKT) cells are rare but potent
innate regulatory cells capable of immune modulation after trans-
plantation via robust production ofTh1/Th2 cytokines, as well as tu-
mor immunosurveillance via direct cytotoxicity. Protocols to expand
iNKT cells and tailor their cytokine secretion would broaden
their application in transplant immunotherapy. We have optimized
a protocol for ex vivo expansion of highly purified human
CD31Va241 iNKT cells from a variety of cell sources including hu-
man peripheral blood (PB), bone marrow, and umbilical cord blood.
PB CD31Va241 iNKT cells (. 98% pure by sort) were expanded
using PB-derived autologous APCs, Va24-specific TCR stimulation
without added glycolipids, and low-dose IL-2 and IL-7. This results
inmean. 103-fold expansion, with peak yields at day 14-21 (range, 3
 106 - 7  107 iNKT cells from 103 - 104 starting CD31Va241
cells). Expanded iNKT cells are CD31CD4negVa241 and retain
viability in culture through day 49. At 21 days, these iNKT cells se-
crete high IL-10 and IL-5, moderate IL-4 and IFN-g, and low IL-2
and IL-13 in anti-CD2/CD3/CD28 bead-stimulated Luminex
supernatant assay. Day 21 expanded iNKT cells maintained an IL-
4hiIFN-glo phenotype even with potent Th1-polarizing stimuli
[100 ng/mL of the glycolipid ligand alpha-galactosyl ceramide (a-
GalCer)], and are dose-dependent suppressors of sorted autologous
CD31CD4negVa24neg (. 95% CD31CD81) responders in 72-hr
CFSE MLR. Non-glycolipid activation of day 21 iNKT cells in-
duced high levels of cytolytic effectormolecules, including granzyme
B. We measured cytotoxicity of activated day 21 iNKT cells follow-
ing co-incubation of iNKT cells versus control effector populations
with firefly luciferase-transduced RS4,11 andNalm6 (B-ALL),U937
(monocytic) and K562 (CML) targets. iNKT cell effectors (E) dem-
onstrated dose-dependent cytotoxicity against B-ALL targets (T)
(e.g. Nalm6: 31.2 69.1% at E:T 0.1:1, 32.6 64.4% at E:T 0.5:1,
48.565.7% at E:T 1:1), with no significant cytotoxicity against my-
eloid targets (e.g. K562: 12.3 61.6% at E:T 0.1:1, 14.9 63.0% at
E:T 0.5:1, 14.2 62.6% at E:T 1:1). Our results indicate that human
iNKT cells expressing high levels of Th2 and regulatory cytokines
can be potently expanded ex vivo without exogenous glycolipid stim-
ulation and exert significant cytotoxicity against B-ALL targets. This
supports their potential for application in anti-tumor or regulatory
immunotherapy in the pre- and post-transplant setting.166
ADOPTIVE TRANSFER THERAPY USING EXPANDED MELANOMA-
SPECIFIC T CELLS PROGRAMMED EX VIVO FOR IMPROVED EFFICACY
IN VIVO
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Adoptive cell transfer (ACT) of autologous tumor-infiltrating
lymphocytes (TIL) mediates tumor regression in 50% of Stage
IV melanoma patients previously refractory to all other types of
therapy. Further improvement of this therapy based on current
technology (using OKT3 and allogeneic PBMC) to propagate T
cells has reached a point of diminishing returns due to the techni-
cally cumbersome and resource-intensive production of TIL for
clinical administration. The extended culture times needed to gen-
erate sufficient numbers of TIL typically results in acquisition of
terminally-differentiated T cells with loss of effector memory
(EM) function and reduced antigen specificity, resulting in poor
in vivo persistence and reduced therapeutic potential. Compound-
ing this problem is that TIL cannot be expanded from many mel-
anoma patients, leaving them without an option for cellular
therapy. To improve ACT, here we show that K562 cells can func-
tion as artificial antigen-presenting cells (aAPC) for propagating
melanoma-specific T cells from both TIL and peripheral blood.
K562 were genetically modified to function as ‘‘generic’’ aAPC
for in vitro propagation of T cells with central/effector memory
phenotypes by enforced expression of the costimulatory molecules
CD86 and 41BB-L in addition to membrane-bound versions of the
cytokines IL7/IL15/IL21. As K562 do not express endogenous
HLA A and B molecules engendering allogeneic responses, they
were genetically modified as ‘‘specialized’’ aAPC using the Sleeping
Poster Session I S215Beauty (SB) DNA non-viral transposon/transposase system to ex-
press the melanoma-associated antigens MART-1 and gp100 in
combination with desired HLA molecules.
Table 1. Classical HLA class I molecules used to genetically
modify K562 to function as aAPC and their proportion in the
US population and in melanoma patients at MDACC.
Percent ofHLA
class IAfrican-
American
(% of US
population)Caucasian
(% of US
population)Hispanic
(% of US
population)Asian
(% of US
population)stage IV
melanoma
patients
at MDACCA*0101 11 28 12 3 15
A*0201 23 47 41 18 27
A*0301 19 24 14 2 12
A*1101 5 14 11 41 8
A*2301 21 3 4 1 3
A*2402 6 13 23 34 8
A*3303 8 1 2 22 1
B*0702 16 21 12 5
B*3501 12 13 14 7
B*4403 7 6 11 9
B*5101 2 11 12 13We show that these aAPC selectively propagate melanoma-specific
CD81 T cells from both PBMC and TIL, generating T cells with
an improved memory phenotype, expansion capability, and cytolytic
function compared to TIL generated in standard expansion proto-
cols. By ex vivo manipulation of the microenvironment, we can
thus expand T cells with a younger, less differentiated phenotype
which maintain expression of critical T-cell costimulatory molecules
predicted to improve persistence and antitumor function following
ACT. These data suggest that K562-aAPC can be used as a platform
technology for the robust and rapid manufacturing of clinical-grade
melanoma-specific T cells. Furthermore, this aAPC strategy
broadens the application of T cell therapy so that patients from
whom TIL cannot be expanded may receive immunotherapy.167
MISMATCHED DONOR LYMPHOCYTE INFUSIONS FOR RELAPSED ACUTE
LEUKEMIA FOLLOWING HLA IDENTICAL ALLOGENEIC STEM CELL
TRANSPLANT
McIver, Z.A., Battiwalla, M., Barrett, A.J. National Institutes of Health,
Bethesda, MD
Patients receiving allogeneic SCT for hematological malignancies
who suffer a relapse of their disease post-transplant have limited
treatment options and a poor prognosis. With the exception of pa-
tients with chronic leukemias, standard treatment options achieve
less than a 10% median survival beyond 6 months. The primary ob-
jective of this phase II clinical trial is to evaluate the safety and effi-
cacy of using DLI from a haplo-identical donor to treat relapsed
disease following matched sibling stem cell transplantation (SCT)
in subjects who are not candidates for other treatments. SinceMarch
2008 three patients have been enrolled and received preconditioning
with fludarabine 25mg/m2  5 days and cytoxan 60mg/kg  2 days,
followed by a haploidentical DLI from a family member at a fixed
dose of 1  10*8th CD31 T cells/kg. Median age was 55 years
(range, 40-57). Two patients were enrolled to treat relapsed AML
occurring day 70 and 83, and one patient for ALL relapse occurring
day 91 after SCT. All patients had active disease at time of precondi-
tioning, resistant to standard chemotherapy. Two patients had nor-
mal cytogenetics, and one was positive for FLT3-ITD. All patients
experience a cytokine storm occurring within 12 hours of DLI and
manifesting as a diffuse macular rash, mild transaminitis, and persis-
tent fever (. 40 C) resolving with high dose steroids (1-2 mg/Kg
methylprednisolone). All patients experienced a hematologic remis-
sion of their disease (2 with no evidence of disease on bone marrow
biopsy), and developed marrow aplasia. All patients developed gradeII skin GvHD. Two patients experienced grade III-IV acute GvHD
of liver and GI tract that contributed to death in one patient 18 days
after DLI. Two patients received a haploidentical CD34 selected
stem cell rescue from the same haploidentical donor on days 35
and 38 after DLI to treat persisting cytopenia. Engraftment of all
lineages occurred within 14 days of stem cell infusion. Upon engraft-
ment, one patient was discharged home but died day 103 of recurrent
AML, and one had persistence of pulmonary and hepatic fungal in-
fection that resulted in death on day 64 after DLI. Overall, treatment
of relapsed leukemia in these 3 patients with mismatched DLIs
preconditioned with fludarabine and cytoxan produced a potent
anti-leukemic effect, but was associated with a high incidence of
treatment-related mortality due to acute GvHD andmarrow aplasia.
Table 1.
SurvivalPatientMarrow
AplasiaBacterial
InfectionsFungal
InfectionsSevere
GvHDafter
relapse
(days)Survival
after
DLI (days)Cause
of death1 YES YES NO YES 35 18 TRM2 YES YES Pulmonary NO 190 103 Relapse3 YES YES Pulmonary YES 77 64 TRM168
THE GENERATION OF CLINICAL GRADE ASPERGILLUS FUMIGATUS (AF)
SPECIFIC IMMUNE CELLS FOR ADOPTIVE IMMUNOTHERAPY
Gaundar, S., Clancy, L., Blyth, E., Simms, R., Mickleth, K.,
waiteGottlieb, D. Westmead Millennium Institute and University of Syd-
ney, Westmead, NSW, Australia
Af is responsible for themajority of invasive fungal infections post-
allogeneic HSCT due principally to transplant related neutropenia
and impaired specific immunity. Murine models suggest that the lat-
ter may be amenable to correction with adoptive immunotherapy
providing lymphocytes specific for Af. However, an efficient, repro-
ducible and clinically acceptable method for the expansion of such
cells in humans is not currently available. Specific T cell responses
to fungi are thought to be mediated by CD4 cells of the Th1 and
Th17 type. Recently, we developed a procedure that induces expan-
sion of large numbers of Af specific T cells over a 21 day culture pe-
riod. This procedure incorporates 2 stimulations using autologous
monocyte-derived dendritic cells pulsed with water-soluble antigen,
and subsequent expansion of T cells using IL-2, IL-7 and IL-15. Our
method satisfies clinical regulatory standards. Using water soluble
antigen from an Af isolate (WMAfES001), we expanded T cells
from PBMCs from 5 healthy donors. Median expansion was 38.3
fold following stimulation with WMAfES001 antigen pulsed DCs
compared with 9.0 when stimulated with unpulsed DCs. The
mean percentages of CD3, CD4 and CD8 T cells in WMAfES001
cultures were 96.364.6%, 94.463.3% and 4.363.0% respectively.
The specificity of T cells in 4 cultures was assessed by cytokine pro-
duction upon re-stimulation with DCs pulsed with WMAfES001
and expressed as a fold increase relative to cytokine levels in response
tomock antigen.Median fold increases of 9.6 in IFNg, 8.3 in TNFa,
11.0 in IL-2 and 3.7 in IL-17 were observed in the CD4T cell subset
of WMAfES001 expanded cultures. Amongst the Th1 cytokine
producers, 51.163.2% produced a single cytokine, 40.769.7% pro-
duced double cytokines and 8.366.9% produced all three cytokines.
Stimulation of Af expanded cells with antigen from a clinical Af iso-
late resulted in cytokine production similar to that we observed in
our clinical grade WMAfES001 expanded cultures. No cytokine
response was observed in CD8 lymphocytes fromWMAfES001 cul-
tures, unmanipulated PBMCs, or cultures expanded in the absence of
WMAfES001 antigens. In conclusion, we have generated a clinically
appropriate Af antigen preparation and a reliable procedure for the
expansion of Af specific T cells for cell therapy purposes that results
in high absolute numbers of specific Th1 andTh17 cytokine produc-
ing cells. These cells are ready to be tested clinically in situations of
high Af risk.
